AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Shattuck Labs shares surge 10.77% intraday after HC Wainwright upgrades to 'Buy' with $6 target, citing SL-325's IBD therapy potential.
ByAinvest
Thursday, Dec 4, 2025 10:27 am ET1min read
Shattuck Labs surged 10.77% in intraday trading, driven by HC Wainwright upgrading its rating to "buy" with a $6 price target, citing confidence in its lead candidate SL-325, a potential first-in-class DR3 antibody for inflammatory bowel disease. The company is advancing SL-325 into Phase 1 clinical trials, with the SAD portion initiated in Q3 2025 and completion of SAD/MAD enrollment expected by Q2 2026. Shattuck specializes in therapies for inflammatory and immune-mediated diseases.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet